reglab/statecodes huggingface dataset:
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease › Section 125205.

125205. The department and the State Department of Social Services shall, after consultation with the Genetically Handicapped Persons Program of the department and consumer organizations representing persons with chronic and degenerative conditions, as defined in Section 125210, compile a list of long-term care resources that serve adults with chronic and degenerative conditions, as defined. The list of resources shall include those that have already been identified by the Genetically Handicapped Persons Program as serving persons with Huntington’s disease, Joseph’s disease, and Friedrich’s ataxia, and shall include those that have already been identified by consumer organizations representing persons with chronic and degenerative conditions. The list of resources shall include, but not be limited to, the following:
(a)  Public and private skilled nursing facilities and intermediate care facilities.
(b)  Public and private community residential care facilities.
(c)  Public and private out-of-home long-term care resources such as day activity programs, and in-home support service programs. Nothing in this section shall require the State Department of Health Care Services to undertake a survey of long-term care facilities or programs in the state for the purposes of carrying out the requirements of this section.
The information shall be made available to the public, upon request, through the Genetically Handicapped Persons Program of the department.
(Amended by Stats. 2012, Ch. 23, Sec. 38. (AB 1467) Effective June 27, 2012.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease › Section 125210.

125210. For the purposes of this article, chronic and degenerative diseases shall include those conditions that are neurological and neuromuscular in origin, including such disorders as Huntington’s disease, Friedrich’s ataxia, Joseph’s disease, and other disorders that are determined by the department to be similar in origin and clinical manifestation to the named disorders, and that affect adults.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease › Section 125215.

125215. The department and the State Department of Social Services shall review regulations that currently provide disincentives to providers of in-home and out-of-home long-term care resources, as defined in Section 125205, to accept and serve persons with chronic and degenerative disorders. The review shall be conducted with assistance and input from the Genetically Handicapped Persons Program of the department. These departments shall provide a list of those regulations to the Legislature by September 1, 1982. The regulations subject to review shall be those regulations that do the following:
(a)  Affect the admission of patients to state-licensed skilled nursing facilities, intermediate care facilities, and community residential care facilities.
(b)  Affect the staffing ratios necessary to care for persons with chronic and degenerative conditions, as defined, within those facilities.
(c)  Affect the likelihood of facilities, or of day care programs and in-home support service programs, to refuse the admission of persons with chronic and degenerative conditions, solely on the basis of anticipated jeopardy to their licensing, or on the basis of anticipated liability to the facilities arising from instances where a person’s degenerative condition, by its own clinical merits, results in medical complications that are, in fact, entirely unrelated to the quality of care provided by the facility or program.
(Amended by Stats. 2012, Ch. 23, Sec. 39. (AB 1467) Effective June 27, 2012.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 2 - Long-Term Care for Degenerative Genetic Disease › Section 125220.

125220. The actions undertaken pursuant to this article shall not impose additional state obligations or expenditures for the care of persons with chronic and degenerative conditions, as defined by this article, unless the Legislature enacts a statute specifically appropriating money for the additional obligations or expenditures.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 3 - Huntington s Disease Research and Workshop Grants › Section 125225.

125225. The Legislature hereby finds and declares that:
(a)  Huntington’s disease is a chronic progressive inherited disorder of the central nervous system.
(b)  The constellation of mental and physical symptoms, the insidious onset of the disorder, and the torment of those at-risk, waiting throughout their lives to learn if they have been spared, conspire to make “Huntington’s disease one of the most diabolical diseases known to man.” Each child of a patient with Huntington’s disease has a 50/50 chance of getting the disease.
(c)  Males, females, and all ethnic groups may be affected and there is no effective treatment or cure. Because so little is known about the disease, many people are misdiagnosed and mistreated.
(d)  The suicide rate among Huntington’s disease patients is estimated to be seven times the national rate.
(e)  The advancement of scientific knowledge about Huntington’s disease, that, because of its extraordinary range of symptoms, serves as an excellent prototype for other major chronic genetic, neurologic, and psychiatric illnesses and diseases of aging, such as epilepsy, muscular dystrophy, and Parkinson’s disease, will reveal fundamental scientific information that may lead to treatment, prevention, and ultimately a cure for an array of inherited disorders that affect millions.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 3 - Huntington s Disease Research and Workshop Grants › Section 125230.

125230. The director may establish any rules or criteria for grants under this article as the director deems necessary.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 3 - Huntington s Disease Research and Workshop Grants › Section 125235.

125235. There is hereby created a Scientific Advisory Review Committee. The membership of the committee shall be composed of 11 members who shall be representatives from each of the following:
(a)  Two from the University of California.
(b)  One from Stanford University.
(c)  One from the California Institute of Technology.
(d)  One from the Hereditary Disease Foundation.
(e)  One from the City of Hope.
(f)  One from the Health and Welfare Agency appointed by the Secretary of the Health and Welfare Agency.
(g)  One appointed by the Speaker of the Assembly.
(h)  One appointed by the President pro Tempore of the California Senate.
(i)  One from the National Huntington’s Disease Association.
(j)  One from the Committee to Combat Huntington’s Disease.
Except as otherwise provided in this section, members of the committee shall be appointed by the director, who shall make the appointments based upon recommendations from the entity or organization represented.
The members of the committee shall serve at the pleasure of the appointing power. The members of the committee shall serve without compensation, but shall be reimbursed for necessary and travel expenses incurred in the performance of the duties on the committee.
The Scientific Advisory Review Committee is hereby abolished one year after the grants under this article have been made by the director.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 3 - Huntington s Disease Research and Workshop Grants › Section 125240.

125240. Pursuant to the rules or criteria as the director may deem necessary, the Scientific Advisory Review Committee shall review and recommend approval of grant applications and monitor programs receiving grants under this article.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 3 - Huntington s Disease Research and Workshop Grants › Section 125245.

125245. The director may make grants as follows:
(a)  Individual research grants to scientists and facilities residing in this state that have research experience with basic and clinical investigations on Huntington’s disease and related disorders. Individual research grants shall not exceed twenty thousand dollars ($20,000).
(b)  Interdisciplinary workshop grants to scientists and facilities for the purposes of facilitating interchange among an interdisciplinary group of investigators regarding problems in the treatment and care of patients as well as basic research, all of which may be applicable to a variety of genetic or neuro-degenerative disorders in addition to Huntington’s disease. Individual workshop grants shall not exceed twelve thousand five hundred dollars ($12,500).
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 3 - Huntington s Disease Research and Workshop Grants › Section 125250.

125250. Not more than 10 percent of any money appropriated for purposes of this article shall be utilized for the administration of this article.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 4 - Alzheimer s Disease › Section 125275.

125275. (a)  The Legislature finds that Alzheimer’s disease, a devastating disease which destroys certain vital cells of the brain, affects more than 1,500,000 Americans. The Legislature also finds that Alzheimer’s disease and related disorders are responsible for 50 percent of all nursing home admissions and Alzheimer’s disease is the fourth leading cause of death in adults. The Legislature recognizes that the disease has serious emotional, financial, and social consequences for its victims and their families.
(b)  The Legislature recognizes that the cause of Alzheimer’s disease is presently unknown, and there is no established treatment which can cure, reverse, or stop the progression of Alzheimer’s disease. The Legislature also recognizes that research is the only hope for victims and families. The Legislature finds that existing diagnostic and treatment centers have improved the quality of care available to the victims of Alzheimer’s disease and increased knowledge with respect to Alzheimer’s disease and related disorders. These centers provide clinical opportunities for research and facilitate the collection of essential data regarding Alzheimer’s disease and related disorders, while at the same time providing valuable services such as information and referral, counseling, and training to victims and their families. It is the intent of the Legislature, in enacting this article, to encourage the establishment of geographically dispersed diagnostic and treatment centers for Alzheimer’s disease within every postsecondary higher educational institution with a medical center, and to encourage research to discover the cause of, and a cure for, Alzheimer’s disease.
(c)  The functions of the diagnostic and treatment centers shall be designed to serve all of the following purposes:
(1)  To provide diagnostic and treatment services and improve the quality of care to victims of Alzheimer’s disease.
(2)  To increase research by faculty and students in discovering the cause of, and a cure for, Alzheimer’s disease.
(3)  To provide training, monitoring, consultation, and continuing education to the families of those who are affected by Alzheimer’s disease.
(4)  To increase the training of health care professionals with respect to Alzheimer’s disease and other acquired brain impairments to the extent that the centers have the requisite expertise.
(d)  The diagnostic and treatment centers may collaborate with the Statewide Resources Consultant designated pursuant to Section 4364 of the Welfare and Institutions Code, to the extent that the centers deem necessary in order to fulfill the functions set forth in subdivision (c).
(Added by renumbering Section 412 (as amended by Stats. 1995, Ch. 551) by Stats. 1996, Ch. 1023, Sec. 134. Effective September 29, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 4 - Alzheimer s Disease › Section 125280.

125280. (a)  Any postsecondary higher educational institution with a medical center may establish diagnostic and treatment centers for Alzheimer’s disease subject to the department’s grants review process.
(b)  The department shall administer grants to postsecondary higher educational institutions that establish diagnostic and treatment centers pursuant to subdivision (a).
(c)  Funds appropriated for the purposes of this article by the Statutes of 1987 shall first be used to maintain and enhance, as determined by the department, existing centers and to prevent program cutbacks under subdivision (b).
(d)  Alzheimer’s disease grants for the purpose of establishing a diagnostic and treatment center shall be used only for the purposes of this article, including, but not limited to, all of the following:
(1)  Salary and benefits for faculty, residents, fellows, and staff of the diagnostic and treatment center.
(2)  Costs of supplies and equipment.
(3)  Research grants for faculty research to discover the cause of, and a cure for, Alzheimer’s disease.
(4)  Research grants for students, residents, and fellows.
(5)  General administrative costs of up to 8 percent of the total grant.
(e)  The department shall establish criteria for requests for Alzheimer’s disease diagnostic and treatment center grants and Alzheimer’s disease research grants, and for program evaluation.
(f)  No grant awarded pursuant to this article shall be approved for any amount that exceeds 25 percent of the total amount of funds appropriated for this purpose in the 1987–88 Regular Session of the Legislature.
(g)  The department shall administer a grant program for the purpose of research into the causes, treatment, cure, strategies for coping with, prevention, incidence, and prevalence of Alzheimer’s disease and related disorders. Priority shall be given to grant applications for feasibility studies, startup grants, and matching funds for federal and privately funded research grants. Consideration shall be given to proposals that link service delivery and collect data relative to patient care and the delivery of social services. This research may include, but is not limited to, examinations and recommendations for the improvement of the family, community-based and health care support systems available to Alzheimer’s disease victims, and their caregivers.
(h)  Upon request, the department shall make available to the Legislature information regarding the progress of the grant programs established pursuant to this article.
(i)  The department shall reduce any grant pursuant to this article by the amount of any federal funds available for the same purposes to the same grantee.
(Added by Stats. 1995, Ch. 415, Sec. 8. Effective January 1, 1996.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 4 - Alzheimer s Disease › Section 125281.

125281. From funds appropriated to the department in the Budget Act of 2016 for these purposes, the department shall allocate funds to the diagnostic and treatment centers for Alzheimer’s disease established pursuant to Section 125280 to be used for all of the following purposes:
(a) To determine the standard of care in early and accurate diagnosis drawing on peer-reviewed evidence, best practices, Medicare and Medicaid policy and reimbursement, and experience working with patients seeking services at a center.
(b) To conduct targeted outreach to health professionals through medical school instruction, hospital grant rounds, continuing education, community education, and free online resources.
(c) To provide low-cost, accessible detection and diagnosis tools that the center shall make available via open source portals of the postsecondary higher educational institution that established the center. Furthermore, the department shall post these tools on its Internet Web site to serve as a resource for the state.
(d) To endorse and disseminate low-cost, accessible detection and diagnosis tools for broad use by health professionals practicing in a variety of settings.
(e) To address unique health disparities that exist within diverse populations, with special focus and attention on reaching African Americans, Latinos, and women.
(f) To evaluate the educational effectiveness and measure the impact of these efforts, including pretests and posttests for health professionals, metrics, and documented practice change.
(Added by Stats. 2016, Ch. 30, Sec. 8. (SB 833) Effective June 27, 2016.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 4 - Alzheimer s Disease › Section 125283.

125283. (a) The Center for Healthy Communities, within the State Department of Public Health, shall, on or before January 1, 2021, update the 2009 Alzheimer’s Disease Facts and Figures in California: Current Status and Future Projections to quantify the burden of Alzheimer’s disease on at-risk and underrepresented populations, including African Americans, Asian-Pacific Islanders, Latinos, Hispanics, and women.
(b) This section shall remain in effect only until January 1, 2025, and as of that date is repealed.
(Added by Stats. 2018, Ch. 737, Sec. 1. (SB 1292) Effective January 1, 2019. Repealed as of January 1, 2025, by its own provisions.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 4 - Alzheimer s Disease › Section 125285.

125285. The department shall provide public and professional education on Alzheimer’s disease to educate consumers, caregivers, and health care providers, and to increase public awareness. If the department determines that contracts are required to implement this section, the department may award these contracts on a sole source basis. The contracts shall not be subject to Part 2 (commencing with Section 10100) of Division 2 of the Public Contract Code. Notwithstanding any other provision of law, the balance of funds appropriated pursuant to the Budget Act of 2000 for Alzheimer’s disease education shall be available for encumbrance and expenditure until June 30, 2003.
(Added by Stats. 2000, Ch. 93, Sec. 35. Effective July 7, 2000.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act › Section 125286.10.

125286.10. This article shall be known, and may be cited, as the Standards of Service for Providers of Blood Clotting Products for Home Use Act.
(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act › Section 125286.15.

125286.15. The Legislature hereby finds and declares all of the following:
(a) Hemophilia is a rare, hereditary, bleeding disorder affecting at least 4,000 persons in California and is a chronic, lifelong, and incurable, but treatable, disease.
(b) Von Willebrand disease is a human bleeding disorder caused by a hereditary deficiency or abnormality of the von Willebrand factor in human blood, which is a protein that helps clot blood. Von Willebrand disease is a chronic, lifelong, incurable, but treatable, disease affecting at least 360,000 Californians.
(c) Until the 1970s, people with severe hemophilia suffered from uncontrollable internal bleeding, crippling orthopedic deformities, and a shortened lifespan. More recently, the production of highly purified blood clotting factors has provided people with hemophilia and other bleeding disorders the opportunity to lead normal lives, free of pain and crippling arthritis.
(d) The preferred method of treatment of hemophilia today is intravenous injection, or infusion, of prescription blood clotting products several times per week, along with case management and specialized medical care at a federally designated regional hemophilia treatment center.
(e) Pharmacies and other entities specializing in the delivery of blood clotting products and related equipment, supplies, and services for home use form a growing enterprise in California.
(f) Timely access to federally designated regional hemophilia centers and appropriate products and services in the home, including infusion of blood clotting products and related equipment, and supplies and services for persons with hemophilia and other bleeding disorders, reduces mortality and bleeding-related hospitalizations according to the federal Centers for Disease Control and Prevention and the Medical and Scientific Advisory Council of the National Hemophilia Foundation.
(g) Eligible persons with hemophilia or other bleeding disorders may receive treatment through the Genetically Handicapped Persons Program, the California Children’s Services Program, and the Medi-Cal program.
(h) For the benefit of persons with hemophilia or other bleeding disorders, the purposes of this article are to do the following:
(1) Establish standards of service for entities that deliver blood clotting products and related equipment, supplies, and services for home use.
(2) Promote access to a full range of essential, cost-effective, lifesaving, blood clotting products and related equipment, supplies, and high-quality services for home use for persons with hemophilia and other bleeding disorders.
(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act › Section 125286.30.

125286.30. The California State Board of Pharmacy shall administer and enforce this article.
(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 2 - Genetic Disease Services › ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act › Section 125286.35.

125286.35. Nothing in this article shall apply to either hospital pharmacies or health system pharmacies that dispense blood clotting products due only to emergency, urgent care, or inpatient encounters, or if an inpatient is discharged with a supply of blood clotting products for home use.
(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.10.

125290.10. General—Independent Citizen’s Oversight Committee (ICOC)
This chapter implements Article XXXV of the California Constitution, which established the California Institute for Regenerative Medicine (institute).
(Added November 2, 2004, by initiative Proposition 71, Sec. 5. Note: Prop. 71 is titled the California Stem Cell Research and Cures Act.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.15.

125290.15. Creation of the ICOC
There is hereby created the Independent Citizen’s Oversight Committee, hereinafter, the ICOC, which shall govern the institute and is hereby vested with full power, authority, and jurisdiction over the institute.
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.25.

125290.25. Majority Vote of Quorum
Actions of the ICOC may be taken only by a majority vote of a quorum of the ICOC.
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.55.

125290.55. Scientific and Medical Accountability Standards Working Group
(a) Membership
The Scientific and Medical Accountability Standards Working Group shall have 19 members as follows:
(1) Five ICOC members from the 10 groups that focus on disease-specific areas described in paragraphs (3), (4), and (5) of subdivision (a) of Section 125290.20 or from the members appointed pursuant to paragraph (6) of subdivision (a) of Section 125290.20.
(2) Nine scientists and clinicians nationally recognized in the field of pluripotent and progenitor cell research.
(3) Four medical ethicists.
(4) The Chairperson of the ICOC.
(b) Functions
The Scientific and Medical Accountability Standards Working Group shall have the following functions:
(1) To recommend to the ICOC scientific, medical, and ethical standards.
(2) To recommend to the ICOC standards for all medical, socioeconomic, and financial aspects of clinical trials and therapy delivery to patients, including, among others, standards for safe and ethical procedures for obtaining materials and cells for research and clinical efforts for the appropriate treatment of human subjects in medical research consistent with paragraph (2) of subdivision (b) of Section 125290.35, and to ensure compliance with patient privacy laws.
(3) To recommend to the ICOC modification of the standards described in paragraphs (1) and (2) as needed.
(4) To make recommendations to the ICOC on the oversight of funded research to ensure compliance with the standards described in paragraphs (1) and (2).
(5) To advise the ICOC, the Scientific and Medical Research Funding Working Group, and the Scientific and Medical Research Facilities Working Group, on an ongoing basis, on relevant ethical and regulatory issues.
(Amended November 3, 2020, by initiative Proposition 14, Sec. 15. Effective on December 16, 2020. Note: This section was added on Nov. 2, 2004, by initiative Prop. 71.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.71.

125290.71. Under the guidance of the ICOC, the institute shall, by January 31, 2012, create a transition plan addressing the expiration of current bond funding. A copy of the transition plan shall be transmitted to the Governor, the Controller, and the Legislature within 30 days of its completion.
(Added by Stats. 2010, Ch. 637, Sec. 7. (SB 1064) Effective January 1, 2011.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.72.

125290.72. Expand Alpha Stem Cell Clinic Program and Establish Community Care Centers of Excellence Program
(a) The institute shall expand the Alpha Stem Cell Clinic Program and establish the Community Care Centers of Excellence Program to fund the establishment of centers of excellence where clinical trials are conducted and treatments and cures are made available for all patients. The goal of the Community Care Centers of Excellence Program is to expand the capacity of the Alpha Stem Cell Clinic Program to promote access to human clinical trials and the accessibility of treatments and cures arising from institute-funded research for patients in California by establishing geographically diverse centers of excellence to conduct clinical trials and to seek to make the resulting treatments and cures broadly available to California patients.
(b) The institute shall prioritize the funding of applications for Community Care Centers of Excellence that enhance the geographic distribution of Community Care Centers of Excellence across the state, considering the location of the Alpha Stem Cell Clinics, to promote patient access. The institute shall prioritize applications for Alpha Stem Cell Clinics and Community Care Centers of Excellence that offer matching funds or verified in-kind support, consistent with the highest medical standards, as established by the governing board of the institute.
(c) Applications for Alpha Stem Cell Clinic and Community Care Centers of Excellence grants shall be required to include a plan for enhancing access to clinical trials for California patients and making treatments and cures that arise from institute-funded research more widely available to California patients, including addressing how the applicant will support the ancillary hospital and access costs of patients participating in clinical trials to enhance access to trials for California patients, regardless of their economic means and geographical location.
(d) Alpha Stem Cell Clinic and Community Care Centers of Excellence awards shall be made pursuant to the procedures set forth in Article 1 (commencing with Section 125290.10) of Chapter 3 of Part 5 of Division 106.
(Added November 3, 2020, by initiative Proposition 14, Sec. 4. Effective on December 16, 2020.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.74.

125290.74. Shared Research Laboratory Program
(a) The institute shall reestablish a Shared Research Laboratory Program to provide funding to academic and nonprofit research institutions in California for specialized instrumentation, a supply of cell lines, culture materials, and instruction and training in research methods and techniques. Awardees of Shared Research Laboratory grants shall be required to offer use of the research laboratory to investigators conducting research at the awardee institution and provide a reasonable access plan for neighboring research institutions, and to offer instruction and training opportunities to students and investigators at the awardee institution and provide a reasonable access plan for neighboring research institutions.
(b) The institute shall prioritize the funding of applications that enhance the geographic distribution of Shared Research Laboratories across the state and applications that offer matching funds or verified in-kind support.
(c) Shared Research Laboratory Program awards shall be made pursuant to the procedures set forth in Article 1 (commencing with Section 125290.10) of Chapter 3 of Part 5 of Division 106.
(Added November 3, 2020, by initiative Proposition 14, Sec. 6. Effective on December 16, 2020.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.76.

125290.76. Advisory Task Forces
(a) Membership
The chairperson and the president may appoint one or more advisory task forces to provide expert guidance to address specific objectives in areas under the institute’s jurisdiction, including scientific, policy, ethical, financial, and technical matters. The chairperson and president shall each appoint an equal number of members with expertise in the area or areas for which advice is sought, including at least one member who has a patient advocate perspective.
(b) Functions
The advisory task forces shall advise the board through the chairperson and the president, regarding scientific, policy, financial, ethical, and technical matters under the institute’s jurisdiction.
(c) Operations
(1) The advisory task forces shall be advisory only and their operations shall be subject to the requirements applicable to working groups pursuant to Section 125290.50, provided that the advisory task forces shall meet in public when they vote on policy recommendations.
(2) Members of the advisory task forces shall be subject to the conflict of interest requirements applicable to members of the working groups, provided that the advisory task forces shall not review, comment upon, or have jurisdiction over, any individual grant or loan approval.
(Added November 3, 2020, by initiative Proposition 14, Sec. 8. Effective on December 16, 2020.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 1 - California Stem Cell Research and Cures Act › Section 125290.80.

125290.80. The intellectual property standards that the ICOC develops shall include:
(a) A requirement that each grantee or the exclusive licensee of the grantee submit a plan to CIRM to afford access to any drug that is, in whole or in part, the result of research funded by CIRM to Californians who have no other means to purchase the drug. The access plan must be consistent with industry standards at the time of commercialization in California, accounting for the size of the market for the drug, and the resources of the grantee or exclusive licensee.
(b) A requirement that the grantee or exclusive licensee either submit the plan required by subdivision (a), seek an extension from CIRM, or notify CIRM of its intention to seek a waiver, within 10 business days following final approval of the drug by the federal Food and Drug Administration. If the grantee seeks an extension, the plan must be submitted within 30 business days following final approval of the drug by the federal Food and Drug Administration. The plan shall be subject to the approval of CIRM, after a public hearing and opportunity for public comment.
(c) A process by which the ICOC may waive the requirement in subdivision (a) if the ICOC determines, after a public hearing, that in the absence of the waiver, development and broad delivery of the drug will be unreasonably hindered or that the waiver will provide significant benefits that equal or exceed the benefits that would otherwise flow to the state pursuant to subdivision (a). The process shall include the requirement that a request for a waiver shall be posted on CIRM’s Internet Web site for a minimum of 10 business days in advance of the public hearing and that CIRM shall notify the Legislature if the ICOC grants a waiver request, including the reasons that justified the waiver request.
(d) Procedures to protect from public disclosure proprietary information submitted by grantees and exclusive licensees to CIRM pursuant to this section.
(Added by Stats. 2010, Ch. 637, Sec. 8. (SB 1064) Effective January 1, 2011.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.10.

125291.10. This article shall be known, and may be cited, as the California Stem Cell Research and Cures Bond Act of 2004.
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.15.

125291.15. As used in this article, the California Stem Cell Research and Cures Bond Act of 2004, the following terms have the following meaning:
(a) “Act” means the California Stem Cell Research and Cures Bond Act constituting Chapter 3 (commencing with Section 125290.10) of Part 5 of Division 106.
(b) “Board” or “institute” means the California Institute for Regenerative Medicine designated in accordance with subdivision (b) of Section 125291.40.
(c) “Committee” means the California Stem Cell Research and Cures Finance Committee created pursuant to subdivision (a) of Section 125291.40.
(d) “Fund” means the California Stem Cell Research and Cures Fund created pursuant to Section 125291.25.
(e) “Interim debt” means any interim loans pursuant to Sections 125291.60 and 125291.65, bond anticipation notes or commercial paper notes issued to make deposits into the fund and which will be paid from the proceeds of bonds issued pursuant to this article.
(Amended November 3, 2020, by initiative Proposition 14, Sec. 18. Effective on December 16, 2020. Note: This section was added on Nov. 2, 2004, by initiative Prop. 71.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.20.

125291.20. (a) Notwithstanding Section 13340 of the Government Code or any other provision of law, moneys in the fund are appropriated without regard to fiscal years to the institute for the purpose of (1) making grants or loans to fund research and construct facilities for research, all as described in and pursuant to the act, (2) paying general administrative costs of the institute (not to exceed 3 percent of the net proceeds of each sale of bonds), (3) paying the annual administration costs of the interim debt or bonds after December 31 of the fifth full calendar year after this article takes effect, (4) paying the costs of issuing interim debt, paying the annual administration costs of the interim debt until and including December 31 of the fifth full calendar year after this article takes effect, and paying interest on interim debt, if such interim debt is incurred or issued on or prior to December 31 of the fifth full calendar year after this article takes effect, and (5) paying the costs of issuing bonds, paying the annual administration costs of the bonds until and including December 31 of the fifth full calendar year after this article takes effect, and paying interest on bonds that accrues on or prior to December 31 of the fifth full calendar year after this article takes effect (except that such limitation does not apply to premium and accrued interest as provided in Section 125291.70). In addition, moneys in the fund or other proceeds of the sale of bonds authorized by this article may be used to pay principal of or redemption premium on any interim debt issued prior to the issuance of bonds authorized by this article. Moneys deposited in the fund from the proceeds of interim debt may be used to pay general administrative costs of the institute without regard to the 3 percent limit set forth in (2) above, so long as such 3 percent limit is satisfied for each issue of bonds.
(b) Repayment of principal and interest on any loans made by the institute pursuant to this article shall be deposited in the fund and used to make additional grants and loans for the purposes of this act or for paying continuing costs of the annual administration of outstanding bonds.
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.25.

125291.25. The proceeds of interim debt and bonds issued and sold pursuant to this article shall be deposited in the State Treasury to the credit of the California Stem Cell Research and Cures Fund, which is hereby created in the State Treasury, except to the extent that proceeds of the issuance of bonds are used directly to repay interim debt.
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.30.

125291.30. Bonds in the total amount of three billion dollars ($3,000,000,000), not including the amount of any refunding bonds issued in accordance with Section 125291.75, or as much thereof as is necessary, may be issued and sold to provide a fund to be used for carrying out the purposes expressed in this article and to be used and sold for carrying out the purposes of Section 125291.20 and to reimburse the General Obligation Bond Expense Revolving Fund pursuant to Section 16724.5 of the Government Code. The bonds, when sold, shall be and shall constitute a valid and binding obligation of the State of California, and the full faith and credit of the State of California is hereby pledged for the punctual payment of both the principal of, and interest on, the bonds as the principal and interest become due and payable.
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.35.

125291.35. The bonds authorized by this article shall be prepared, executed, issued, sold, paid, and redeemed as provided in the State General Obligation Bond Law (Chapter 4 (commencing with Section 16720) of Part 3 of Division 4 of Title 2 of the Government Code), and all of the provisions of that law, as amended from time to time, except subdivisions (a) and (b) of Section 16727 of the Government Code apply to the bonds and to this article and are hereby incorporated in this article as though set forth in full in this article.
(Amended November 3, 2020, by initiative Proposition 14, Sec. 19. Effective on December 16, 2020. Note: This section was added on Nov. 2, 2004, by initiative Prop. 71.)
2023 California Code › Health and Safety Code - HSC › DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT) › PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS › CHAPTER 3 - California Stem Cell Research and Cures Bond Act › ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004 › Section 125291.40.

125291.40. (a) Solely for the purpose of authorizing the issuance and sale, pursuant to the State General Obligation Bond Law, of the bonds and interim debt authorized by this article, the California Stem Cell Research and Cures Finance Committee is hereby created. For purposes of this article, the California Stem Cell Research and Cures Finance Committee is “the committee” as that term is used in the State General Obligation Bond Law. The committee consists of the Treasurer, the Controller, the Director of Finance, the Chairperson of the California Institute for Regenerative Medicine, and two other members of the Independent Citizens Oversight Committee (as created by the act) chosen by the Chairperson of the California Institute for Regenerative Medicine, or their designated representatives. The Treasurer shall serve as chairperson of the committee. A majority of the committee may act for the committee.
(b) For purposes of the State General Obligation Bond Law, the California Institute for Regenerative Medicine is designated the “board.”
(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)